Gujarat Terce Laboratories Limited

As of June 30, 2026, Gujarat Terce Laboratories Limited carries a market capitalization of 280.49M, placing it among publicly traded companies globally. Its enterprise value stands at 280.49M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Gujarat Terce Laboratories Limited has 7.79M shares outstanding.

As of June 30, 2026, Gujarat Terce Laboratories Limited trades at a trailing price-to-earnings ratio of 13.34.

As of June 30, 2026, Gujarat Terce Laboratories Limited trades at an EV/EBITDA multiple of 9.94 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.61 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 11.74 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 280.49M versus a market cap of 280.49M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 1.90M in revenue per employee across its workforce of 239.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Gujarat Terce Laboratories Limited recorded 8.80M in income tax expense. That works out to an effective tax rate of 29.65, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 29.67M, leaving 20.88M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Gujarat Terce Laboratories Limited's stock has declined approximately 28.05% over the past 52 weeks. The 50-day moving average sits at 38.33, while the 200-day moving average is 38.15.

Over the twelve months ended June 30, 2026, Gujarat Terce Laboratories Limited generated 456.22M in revenue and converted that into 20.88M in net income, yielding earnings per share of 2.67. EBITDA reached 28.22M, while operating income came in at 28.43M.

Over the twelve months ended June 30, 2026, Gujarat Terce Laboratories Limited posted a gross margin of 65.06, reflecting its pricing power and cost economics. The operating margin of 6.23 and net profit margin of 4.58 provide insight into operational efficiency.